Clinical stage immuno-oncology company Genenta Science SPA (NASDAQ: GNTA) on Tuesday announced long-term follow-up data from its glioblastoma multiforme study, TEM-GBM, showing promising survival outcomes in patients treated with Temferon.

Of 38 total participants, 25 received Temferon, and two have now entered the TEM-LT follow-up arm, surviving three years post-surgery. One of these patients has remained progression-free without requiring additional therapies; the other showed initial progression that stabilised without further treatment.

These findings suggest Temferon may play a role in controlling disease progression in glioblastoma, warranting broader investigation. As of April, the two-year survival rate in unmethylated MGMT patients remained at 29%, with median overall survival at 17 months, outperforming historical benchmarks.

Meanwhile, Genenta has initiated patient enrolment in its TEM-GU Phase 1 study targeting genitourinary tumours, including Metastatic Renal Cell Carcinoma. Temferon is being administered at a previously validated safe dose, with the trial exploring its safety and tolerability when used in combination with immune checkpoint or tyrosine kinase inhibitors.